Skip to main navigation
REGENXBIO_Logo-RGB REGENXBIO_Logo-RGB
Corporate Menu
  • About
    • Mission & Values
    • Management Team
    • Board of Directors
  • Nav Technology
  • Therapeutic Programs
    • RGX-314
    • RGX-202
    • RGX-121
    • RGX-111
    • RGX-181
    • RGX-381
  • Patients and Families
    • Gene Therapy
    • Wet AMD
    • Duchenne
    • MPS II
    • MPS I
    • CLN2
    • Expanded Access
  • Partners & Licensees
    • Partners & Licensees Pipeline
  • Media
    • Press Releases
    • Presentations & Publications
  • Investors
    • Stock Information
    • Recent News
    • SEC Filings
    • Corporate Governance
    • Shareholder Services
  • Join Us

Investors

News & Events

Investor Relations
  • Stock Information
  • News & Events
  • SEC Filings
  • Corporate Governance
  • Shareholder Services
Investor Relations
  • News & Events
    • Stock Information
    • News & Events
    • SEC Filings
    • Corporate Governance
    • Shareholder Services

News & Events

01/10/22
REGENXBIO Announces Initiation of Second Pivotal Trial in RGX-314 Clinical Program for the Treatment of Wet AMD Using Subretinal Delivery
01/06/22
REGENXBIO Announces FDA Clearance of IND for Clinical Trial of RGX-202, a Novel Gene Therapy Candidate for Duchenne Muscular Dystrophy

Pagination

  • First page « first
  • Previous page ‹ previous
  • Page 1
  • Page 2
  • Page 3
  • Current page 4
Event Calendar
More events are coming soon.
Aug 17, 2022 | 11:00 AM EDT
H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
Aug 3, 2022 | 4:30 PM EDT
Q2 2022 REGENXBIO Inc. Earnings Conference Call
May 24, 2022 | 10:45 AM EDT
UBS Global Healthcare Conference 2022
May 10, 2022 | 4:00 PM PDT
Bank of America Securities 2022 Healthcare Conference
May 4, 2022 | 4:30 PM EDT
Q1 2022 REGENXBIO Inc. Earnings Conference Call
Apr 26, 2022 | 8:30 AM EDT
Chardan's 6th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
Mar 17, 2022 | 10:45 AM EDT
Barclays Global Healthcare Conference
Mar 1, 2022 | 4:30 PM EST
Q4 2021 REGENXBIO Inc. Earnings Conference Call
Feb 16, 2022 | 8:40 AM EST
11th Annual SVB Leerink Global Healthcare Conference
SIGN UP

Receive updates to stay connected on REGENXBIO programs and our commitment to patients.

Subscribe
Contact Us

9804 Medical Center Drive, Rockville, MD 20850
240.552.8181

Contact Us Menu
General Info | Patient Advocacy | Partners | Investors | Media
Follow Us
REGENXBIO_Logo-RGB

©2022 REGENXBIO Inc. "NAV®" is a registered trademark of REGENXBIO Inc. All rights reserved.

Footer
Privacy Policy | Terms and Conditions